Evidence Explorer · MS-N289 · Nutrition and dietary patterns · Appraised November 10, 2026
A 2026 pilot showed that a 10-hour eating window was feasible for selected older adults receiving long-term hormonal cancer treatment. It did not improve fatigue, frailty or measured activity-rhythm outcomes versus control.
Evidence at a glance
- Population: 30 adults aged 55 years or older; 93% were men. Eligible participants had prostate cancer receiving androgen-deprivation therapy or metastatic breast cancer receiving a CDK4/6 inhibitor plus an aromatase inhibitor.
- Intervention: personalized dietitian counseling for everyone, plus a self-selected 10-hour daytime eating window for the time-restricted group over 12 weeks.
- Design: randomized phase I/II pilot; 24 participants were randomized and 20 completed the program.
- Primary result: retention and adherence supported feasibility. The eating window averaged 9.2 hours with time restriction versus 13.3 hours in control, but there were no between-group effects on fatigue, frailty or rhythm measures.
- Evidence label: feasible in a small selected population; no demonstrated symptom or cancer-control benefit.
- Evidence label: Pilot feasibility; efficacy not demonstrated.
What was studied
The trial was designed first to ask whether older adults living with cancer could follow the schedule, not whether time-restricted eating prolongs survival. Both groups received fortnightly personalized nutrition counseling, so the comparison isolates the added eating window more closely than an uncontrolled program would.
An association between stronger rest–activity rhythm amplitude and less fatigue was exploratory. It does not show that changing meal timing caused a fatigue benefit.
What this evidence cannot establish
The randomized sample was very small, completion was incomplete, and the population was overwhelmingly male. The trial did not measure tumor response, progression or survival as efficacy endpoints. A feasible schedule in a selected, nutritionally stable participant is not evidence that fasting is safe for someone losing weight or struggling to eat.
Safety and practical context
Time restriction can reduce total energy, protein or fluid intake. It deserves particular caution with cancer cachexia, unintentional weight loss, frailty, diabetes medicines, dizziness, dehydration or medications that must be taken with food. ESPEN advises against energy-restricting diets in people who are malnourished or at risk.
Questions for the care team
- Am I maintaining weight, muscle and protein intake well enough to consider an eating-window experiment?
- Could this schedule conflict with diabetes medicines, oral anticancer medicines or medicines that require food?
- What would make us stop—weight loss, dizziness, dehydration, worsening fatigue or inadequate intake?
Sources and identifiers
- 2026 randomized pilot — PMID 42570448; NCT05968144
- ClinicalTrials.gov record — NCT05968144
- 2026 metabolic-diets review — PMID 42926076
- ESPEN practical cancer-nutrition guideline
Funding and conflicts: Funding details were not fully verified from the abstract-level appraisal. The authors declared an editorial-role conflict for one investigator; the paper reports that peer review was delegated.
Source access and dates: Primary reports, registries and official guidance available through the links above were checked November 10, 2026. Last literature search November 10, 2026. Fields unavailable from accessible full text are labeled not reported or not verified rather than assumed absent.
Educational evidence summary, not individualized medical advice. Restrictive diets or supplements should not replace established cancer treatment or adequate nutrition. Symptom, weight, biomarker, laboratory, imaging, pathology or animal findings do not by themselves establish tumor control, recurrence prevention or longer survival.
